Company Analysis

Tevogen Bio Holdings Inc. (TVGN)

Nasdaq: TVGN · Biological Products, (No Diagnostic Substances) · Warren, NJ · filing with the SEC since 2021
Grade3.3
◀ Past 2.6● Present 3.1▶ Future 4.0
7 est.
The companyfiscal 2025, as filed
Revenuen/a
Net income-$26.3M-91.4%
Earnings per share$-8.08-130.9%
Operating cash flow-$12.3M-2.7%
Cash$552,372-56.9%
Debtn/a
Shareholders’ equity-$8.2M-23.4%
Shares, diluted3,319,812+13.2%
Return on equityn/a
The recordfrom its filings
Filings in 202649
Newest filingNov 4 · SCHEDULE 13D/A
Annual reportMar 31, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted3
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$21.6MCash from operations -$11.6Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
22232425
As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 4, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 30, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 16, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Sep 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TVGN · research, not advice